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Abstract
Background: Management of endometrial precancerous lesions has been of much debate due to
inconsistencies in their classification, natural history and histologic diagnosis. Endometrial
hyperplasia constitutes a wide range of histomorphologic features associated with high intra and
interobserver diagnostic variability.
Although traditional microscopic diagnosis is by far the most applicable method and the gold
standard for histomorphologic diagnosis, digitized image analysis has been used as a powerful
adjunct to maximize the histologic data retrieval and to add some detailed objective criteria for
correct diagnosis in difficult cases.
Methods: A series of 100 endometrial curettage specimens with diagnosis of endometrial
hyperplasia or well differentiated adenocarcinoma were blindly reviewed by 5 pathologists; their
intra and interobserver reproducibility determined and further compared to the objective
morphometric data i.e. D-score and volume percent of stroma (VPS).
Results: The results were assessed using the weighted kappa statistics. Mean intraobserver kappa
value was 0.8690 (99.44% agreement). Mean interobserver kappa values by diagnostic category
were: simple hyperplasia without atypia: 0.7441; complex hyperplasia without atypia: 0.3379;
atypical hyperplasia: 0.3473, and well-differentiated endometrioid carcinoma: 0.6428; with a kappa
value of 0.5372 for all cases combined.
Interobserver agreement was in substantial rate for simple hyperplasia (SH) and well differentiated
adenocarcinoma (WDA) but was in fair limit for complex hyperplasia (CH) and atypical hyperplasia
(AH). Intraobserver agreement was almost perfect. The specimens were divided in two groups
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Open Accessaccording to the computerized morphometric analysis: Endometrial Hyperplasia (EH) ( D Score ≥ 1
or VPS ≥ 55%) and Endometrial Intraepithelial Neoplasia (EIN) (D-Score < 1 or VPS < 55%).
Morphometric findings were closely compatible with routine WHO classification made by one
expert pathologist; however; diagnosis of (CH) and (AH) made by other pathologists were not
concordant with morphometric data.
Conclusion: It may be necessary to make some revisions in WHO classification for endometrial
hyperplasia and precancerous lesions.
Background
Endometrial hyperplasia which is believed to increase
the risk of endometrial carcinoma, is a common disease
and comprises a wide spectrum of histological changes
from simple aggregation of the normal-looking prolifer-
ate glands at one extreme to the changes that are difficult
to distinguish from carcinoma at the other end of the
spectrum. [1]
The current classification, introduced by Kurman et al
1985, has been accepted by WHO and ISGP. This
classification considering two criteria (i.e. glandular
complexity and nuclear atypicality) there are four
diagnostic categories of endometrial hyperplasia: simple
hyperplasia (SH), complex hyperplasia (CH), simple
atypical hyperplasia (SAH) and complex atypical hyper-
plasia (CAH). [2-4]
The wide range of histomorphologic presentation of
endometrial hyperplasia is accompanied by high intra
and interobserver variability in diagnostic classification. [5]
Previous studies have shown that only 10–20% of
endometrial hyperplasias progress to carcinoma when
left untreated. [1]
The lack of criteria that could accurately predict the
disease outcome may have been an important cause of
over and under treatment and need for establishment of
a new classification composed of three groups: endo-
metrial hyperplasia (EH), endometrial intraepithelial
neoplasm (EIN) and endometrial carcinoma. [5] EIN is
defined as a neoplastic focal lesion with cytological
features of crowded gland architecture, and a volume
percentage less than 55%, with a minimum size of 1 mm
and careful exclusion of mimics. [6,7]
This alternative strategy that is intended to recognize the
precancerous lesions earlier provides through multivariate
analysis, a subset of objectively measured morphometric
parameters which may predict the subsequent develop-
ment or concurrent carcinoma. Several attempts have been
made to improve the microscopic tissue diagnosis by the
aid of the modern digitized image technology. For
example, Kayser et al worked on a method of automatically
scanning and analyzing routinely stained glass slides
known as virtual microscopy that provides fast and
reproducible data about the object-associated (e.g., cells
and their nuclei) and non-object-associated (background)
tissue components or so-called texture analysis. [8]
Studying on 896 lung cancer slides and using virtual
microscopy they produced non-overlapping compart-
ments on each slide that were subsequently subjected to
texture analysis. With certain calculations performed at
different objective magnifications, they conclude that
this system is a fast and reliable procedure for automated
pre-screening of lung tumor pathology with diagnostic
accuracy of 96–100% that can be made on only 10% of
the original image field without increasing error rate. [8]
An additional advantage of digitized image technology is
its application in the web-based internet communica-
tions also known as telepathology. [8]
Improved image analysis incorporates computer-mea-
sure architectural as well as cytological features into a
cancer predictive formula (D-Score) which is useful for
patient management. [9]
The D-Score has been developed in the early 1980s and
its essential features are of architectural (volume
percentage stroma and outer surface density of glands)
and cytological (standard deviation of the shortest
nuclear axis) nature. [5]
Retrospective studies in the USA, the Netherlands and
Norway confirmed the prognostic value of the D-Score
greatly exceeding the WHO 94 criteria. [5]
D-Score have higher sensitivity (100%), specifity (82%),
positive predictive value (PPV 38%) and negative predictive
value (NPV 100%) compared to WHO 94 with sensitivity
(91%), specifity (58%), PPV (16%) and NPV (99%). [5]
Molecular genetic studies have shown that endometrial
l e s i o n sw i t haD - s c o r el e s st h a n1a r eo f t e nm o n o c l o n a l
physical progenitors of subsequent endometrial
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than 1 are virtually polycolonal. [6,9]
The PTEN tumor suppressor gene is the most frequently
inactivated gene in the premalignant and malignant
phases of endometrioid endometrial cancer. [10,11]
Baak et al revealed EIN lesions that have lost PTEN
t u m o rs u p p r e s s o rf u n c t i o nc o n f e rag r e a t e rc a n c e rr i s k
compared with EIN lesions with an intact PTEN gene. [6]
Materials and methods
A retrospective review of the archives of the Department
of Pathology of Mirza Kolchak Khan Hospital, for the
period of 2001 through 2005 identified 100 patients
who had D&C specimens diagnosed as endometrial
hyperplasia and well differentiated adenocarcinoma.
The material was fixed in buffered formaldehyde,
embedded in paraffin wax and standard hematoxylin
eosin (H&E) stained histological sections were made.
Five pathologists with varying experiences in the field of
gynecologicpathologywhoworkedathospitalsinTehran
University of medical sciences contributed to this study.
The cases were selected to represent four diagnostic
categories including simple hyperplasia(SH) which shows
glands are irregular in size and shape with occasional
dilated, cystic glands lined by pseudostratified uniform and
oval nuclei showing orientation toward the basement
membrane and separated by abundant stroma (fig 1 and
2), complex hyperplasia(CH) composed of closely spaced
glands, highly irregular in size and shape with pseudos-
tratified uniform and oval nuclei (fig 3 and 4), atypical
hyperplasia(AH), a complex hyperplasia which cells show
atypia including irregular, stratified, rounded nuclei with
nucleoli (fig 5 and 6) and well differentiated adenocarci-
noma(WDA), when there are confluent glandular pattern,
an extensive papillary pattern, cribriform bridging, desmo-
plastic or granulation tissue like stroma, and highly atypical
cells (fig 7 and 8, 9 and 10, 11 and 12, 13 and 14).
Twenty-fivecasesfromeachcategorywereincludedandone
representative H&E slide was selected of each case. To assess
interobserver variability slides were randomly labeled from
1 to 100, evaluated by 5 pathologists and presumptive
diagnoses were recorded in a checklist. For intraobserver
evaluation one expert gynecopathologist examined all of
the slides twice within a period of two months.
The checklists included four diagnostic categories (SH, CH,
AH and WDA). After data collection the checklists were
coded and statistically analyzed using the STATA-8
statistical software and weighted kappa test. Data analysis
evaluated interobserver and intraobserver agreement using
the (Kappa) statistic, a measure of agreement between
observers that attempts to correct for chance agreement.
Within the positive values of kappa, given interpretations
used in this study were scaled as: 0.00–0.20 = slight, 0.21–
0.40 = fair 0.41–0.60 = moderate, 0.61–0.80 = substantial
and 0.80–1.00 = almost perfect [12]
The correlation coefficient between morphologic data and
results of morphometric analysis is about 80%, [13] so 55
out of 100 H&E slides were selected randomly which
yielded appropriate material for morphometric analysis.
Figure 1
Simple hyperplasia. Glands are in various size with
occasional dilated, cystic glands separated by abundant
stroma. (Low power).
Figure 2
Simple hyperplasia. Glands are lined by pseudostratified
uniform and oval nuclei. (High power).
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regions on H&E stained sections was performed using
the Leica IM 500® (V.4.R117) software incorporated into
the digitized light-microscope.
For each sample the D-Score was calculated, using three
features include 1) volume percentage of stroma (VPS),
which assesses the percentage of endometrial tissue
composed of stroma (i.e., the inverse of glandular
percentage, a measure of crowding) 2) standard devia-
tion of shortest nuclear axis (SDSNA), which reflects
nuclear pleomorphism and 3) gland outer surface
density (out SD), which is a measurement of basement
membrane length about the endometrial glands (mea-
surement of gland complexity) and the following
formula:
D-score = 0.6229 + (0.0439 × VPS) – [3.9934 ×
Ln (SDSNA)] – (0.1592 × outSD)
[3-5,14] Measurement of these features performed on
9–11 images taken from the most representative
Figure 4
Complex hyperplasia. The glands are separated by scant
endometrial stroma from each other. The nuclei are uniform
and oval. (High power).
Figure 5
Atypical hyperplasia. The glands are closely back to back
with scant intervening stroma and highly irregular in size and
shape. (low power).
Figure 6
Atypical hyperplasia. Back to back glands show stratified
round nuclei with nucleoli. (High power).
Figure 3
Complex hyperplasia. The glands are closely back to back
with scant intervening stroma and highly irregular in size and
shape. (Low power).
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minimum size of 1 mm and careful exclusion of mimics
and non hyperplastic areas [7,14]. Values of D-Score ≥ 1
or VPS ≥ 55% were defined as one group and D-Score<1
or VPS<55% defined as the other.
In brief, VPS was measured on histological images (40 ×
objective magnification (field diameter 340 μm) with a
88 point grid or graticule (weibel grid with 2-point
length 28.3 μm), and the tissue underlying each point
was scored visually from the ocular lens of microscope as
stroma, epithelium or gland lumen. Results from a total
of 400–600 points were tallied and the VPS was
calculated as the number of stromal points divided by
the total points counted. (Range of 14–75%)
Intersections of gland outer surfaces with calibrated
horizontal lines of the weibel grid were tallied and the
Figure 8
Endometrial adenocarcinoma. Confluent growth
pattern of glands with no intervening endometrial stroma or
loose granulation tissue like stroma. (High power).
Figure 9
Endometrial adenocarcinoma. Confluent growth
pattern of glands with no intervening endometrial stroma.
(Low power).
Figure 10
Endometrial adenocarcinoma. Confluent growth
pattern of glands with no intervening endometrial stroma
and severe nuclear atypia. (High power).
Figure 7
Endometrial adenocarcinoma. Closely back to back
glands without intervening endometrial stroma and with
granulation tissue like stroma and cribriform pattern. (Low
power).
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formula:
Out SD
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Nuclear morphometry was preformed on at least 150
randomly selected nuclei and the shortest nuclear axis
was calculated by sending results to Microsoft Excel®
program followed by nuclear mean and SD determina-
tion. Measurement was terminated when the coefficient
of variation went below 5% (range of 0.68–1.52)
Results
For interobserver diagnostic agreement, using the diag-
nosis given by each pathologist on each diagnostic
round, kappa results show significant differences in
diagnostic groups, with highest agreement in SH and
WDA groups and lowest agreement in CH and AH
groups. (Table 1)
Table 2, lists intraobserver agreement of the expert
gynecopathologist on two separate diagnostic rounds.
Kappa results show significant agreement in all diag-
nostic groups.
Figure 12
Endometrial adenocarcinoma. The glands show
cribriform bridging. (High power)
Figure 13
Endometrial adenocarcinoma. Extensive papillary
pattern. (Low power)
Figure 14
Endometrial adenocarcinoma. Papillary growth pattern
of glands with stratified nuclei and mild nuclear atypia (High
power)
Figure 11
Endometrial adenocarcinoma. Cribriform pattern of
glands. (Low power).
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of computerized morphometric data (VPS and D-Score)
with pathologist diagnosis subgroup, statistically ana-
lyzed with post HOC test and shuffle exam for three
pathologists.
According to diagnosis in 01t1 (Observer 1 Time 1),
O2t1 (Observer 2 Time 1) & O3t1 (Observer 3 Time 1)
Compared assessment of different diagnostic groups
with D-Score results show high concordance and ability
in O1t1 (Observer 1 Time 1) for classification and
differentiation of endometrial hyperplasia subgroups
but overlapping results in differentiation of CH with AH
and AH with WDA groups in O2t1 (Observer 2 Time 1)
a n dC Hw i t hA Hi nO 3 t 1( O b s e r v e r3T i m e1 ) .
Case by case comparison of computerized VPS (cut-off
range 55%) and D-Score (cut-off range 1) with pathol-
ogist diagnosis in four diagnostic variables analyzed with
kruss-kall Wallis test are shown in tables 3 and 4.
Discussion
Endometrial carcinoma is the most common female genital
tractmalignancyindevelopedcountries.[15]Endometrioid
and papillary serous carcinomas have been recognized as
two major clinicopathologic subtypes of this cancer. [15]
Endometrioid subtype may arise in background of
endometrial hyperplasia at a younger age while the
high grade in an older age group. [15]
The WHO 94 endometrial hyperplasia classification
system will continue to play an active role in the daily
practice of many pathologists but is plagued by poor
diagnostic reproducibility and the lack of a solid
statistical foundation on therapeutic context.
It is important to characterize high or low risk groups
before initiation of therapy, because about 1–28% of
hyperplasias progress to carcinoma, depending on the
degree of severity. [14]
Considering the combined interobserver agreement level of
"moderate" attained in this study and the previously
reported results as "fair" by Skov (1997); "substantial" by
Kendall (1998) and "moderate" by Bergeron(1999) it seems
that WHO 94 classification system needs essential improve-
ments by an entirely new approach rather than minor
revisions. [16-18]EIN classification system (EH-EIN-CA) is
the best documented alternative based on extensive mor-
phological, genetic molecular and clinical outcome data.
This new molecular genetic-based and morphometric-
based classification differs from the WHO 94, which is
based entirely on histological findings. [14]
Diagnosis of EIN is possible with assessment of D-Score
and VPS morphometrical parameters i.e. lesions with
D-Score<1 or VPS<55% are classified as EIN. It should be
emphasized that morphometric studies of endometrial






99.44% 57.60 0.8690 0.0000
Table 3: Agreement table of diagnostic groups' basis on VPS
VPSCAT(O1T1) VPSCAT(O2T1) VPSCAT(O3T1)



























































SH: Simple Hyperplasia, CH: Complex Hyperplasia, AH: Atypical Hyperplasia, WDA: Well Differentiated Adenocarcinoma.
Table 1: Diagnostic interobserver agreement
Diagnosis Kappa Agreement Probe >Z
SH 0.7741 Substantial <0.0001
CH 0.3379 Fair <0.0001
AH 0.3473 Fair <0.0001
WDA 0.6428 Substantial <0.0001
Combined 0.5372 Moderate <0.0001
SH: Simple Hyperplasia, CH: Complex Hyperplasia, AH: Atypical
Hyperplasia, WDA: Well Differentiated Adenocarcinoma
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nostic combination of quantitative architectural and
nuclear features that corresponds well with both cancer
risk and biologic lesion properties [6,9] but our focus in
this study was to assess diagnostic reproducibility and
comparison of results with D-Score and VPS rather than
to correlate the diagnosis with outcome. Therefore
THERE WAS NO GOLD STANDARD. With grouping of
different diagnostic subgroups according to D-Score
results, interpretative patterns of individual pathologists
fell into two distinctive classes:
One with high concordance and 95% rate of confidence
interval in all subgroups but those two others with
overlapping results, especially in diagnoses of CH with
AH that show lowest rate of reproducibility in all
studies.
Compared VPS and D-Score results rendered highly
concordant replicate results.
Case by case comparison of VPS (cut-off range 55%) and
computerized D-Score (cut-off range 1) with pathologist
diagnosis is shown in tables 3 and 4. As the histological
diagnosis goes from benign (SH) to malignant (WDA)
the VPS decreases to <55% and D-Score becomes <1;
however; there is a major difference between 3 pathol-
ogists in CH category. In other words, the second and the
third pathologists (O2 and O3) have probably "under
diagnosed" a premalignant or even malignant lesion as
CH. This may result in substantially divergent guidance
to the gynecologist and incorrect management such as
medical therapy instead of hysterectomy.
In conclusion, diagnosis of endometrial hyperplasia and
carcinoma with WHO-defined nomenclature may be
problematic, mainly due to stylistic differences between
individuals and inherent poor reproducibility of the
broad range of diagnoses from benign to malignant.
Limitation of borderline or precancerous lesions into
one category (EIN) recognized by objective morphome-
try will probably simplify the diagnosis and improve the
patient's management.
Measurement of VPS – by far the most predictive
component of the D-score – can be accomplished simply
by applying an inexpensive ocular grid into an ordinary
microscope eyepiece and counting the specified points
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